Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data
Open Access
- 30 May 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 182 (2), 418-426
- https://doi.org/10.1111/bjd.18179
Abstract
Background Dupilumab is the first biologic registered for the treatment of moderate‐to‐severe atopic dermatitis (AD), and efficacy was shown in phase III clinical trials (primary outcome at week 16 was reached in 38% of patients). Currently, there are limited daily practice data available for dupilumab, especially when it is combined with systemic immunosuppressants. Objectives To evaluate dupilumab treatment in daily practice in patients with AD. Methods In this observational cohort study, we prospectively included all adult patients with AD who had been treated with dupilumab in two university hospitals in the Netherlands. Concomitant systemic immunosuppressive treatment was monitored. Physician‐reported outcome measures and patient‐reported outcome measures (PROMs) after ≥ 12 weeks of follow‐up were analysed. We used a linear mixed‐effects model to determine changes in scores during follow‐up. Results Ninety‐five patients were included. Of these, 62 patients were using systemic immunosuppressants at baseline; the use of systemic immunosuppressants was continued during dupilumab treatment in 43 patients. From baseline to 16 weeks of treatment, the estimated mean Eczema Area and Severity Index score (0–72) decreased from 18·6 [95% confidence interval (CI) 16·0–21·4)] to 7·3 (95% CI 5·4–10·0), and the estimated mean PROMs showed a decrease of 41–66%. Investigator's Global Assessment 0 or 1 (clear/almost clear) was reached in 38% of the patients. Five patients discontinued dupilumab treatment due to side‐effects or ineffectiveness. Eye symptoms and orofacial (nonocular) herpes simplex virus (HSV) reactivation were reported in 62% and 8% of the patients, respectively. Conclusions Dupilumab treatment in daily practice shows a clinically relevant improvement of physician‐reported outcome measures and PROMs, which is in line with efficacy data from clinical trials. Besides frequently reported eye symptoms and orofacial (nonocular) HSV reactivation, there were no apparent safety concerns.Keywords
Funding Information
- ZonMw
This publication has 39 references indexed in Scilit:
- Effective Use of Dupilumab in Managing Systemic Allergic Contact DermatitisDermatitis®, 2018
- Dupilumab: A Review in Moderate-to-Severe Atopic DermatitisAmerican Journal of Clinical Dermatology, 2018
- Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part IIJournal of the European Academy of Dermatology and Venereology, 2018
- Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part IJournal of the European Academy of Dermatology and Venereology, 2018
- Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statementBritish Journal of Dermatology, 2018
- When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema CouncilJournal of the American Academy of Dermatology, 2017
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisNew England Journal of Medicine, 2016
- Atopic dermatitisThe Lancet, 2016
- Patch Test Results in Psoriasis Patients on BiologicsDermatitis®, 2014
- Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveysThe Lancet, 2006